Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Illumina (NASDAQ:ILMN) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 6, 2025, after market close. The company will host a conference call at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
CEO Jacob Thaysen and CFO Ankur Dhingra will lead the conference call to discuss financial and operating results with analysts, investors, and other interested parties. The live webcast will be accessible through Illumina's Investor Info section, with participants advised to join at least ten minutes before the scheduled start time. A replay will be available on the company's website for a minimum of 30 days following the event.
Illumina (NASDAQ: ILMN) has announced significant updates to its NovaSeq X Series, including a new single-flow-cell system, software upgrade v1.3, and new 25B kits. The single-flow-cell system offers the same quality and speed as the NovaSeq X Plus at a more accessible cost for lower-volume labs. The v1.3 software upgrade enhances sequencing performance with improved accuracy and higher yields.
The company began shipping new NovaSeq X 25B 100-cycle and 200-cycle kits in December, optimized for counting applications and assays at scale. Additionally, Illumina launched Single-Cell Prep (formerly Fluent PipSeq V), compatible with NextSeq 1000/2000, NovaSeq 6000, and NovaSeq X platforms. This technology enables scalable experiments from hundreds to millions of cells, offering lower equipment and per-cell costs.
Illumina, a global genomics leader, showcases employee perspectives on working in genomics technology through a video feature. The company highlights how their work impacts global human health through next-generation sequencing solutions across research, clinical, and applied markets. Three Illumina professionals share their experiences and motivations for working at the company, emphasizing their contribution to advancing personalized healthcare. The company's technology supports innovations in various fields, including oncology, reproductive health, genetic disease, microbiology, agriculture, and forensic science.
Ovation.io and Illumina (NASDAQ: ILMN) announced a collaboration to advance precision medicine by combining Illumina's next-generation sequencing platforms with Ovation's 1.6+ million sample biobank. The partnership aims to create comprehensive clinico-genomic datasets for non-oncology indications where current data is insufficient.
The collaboration will initially focus on pilot datasets in liver disease, chronic kidney disease, and GLP-1 receptor agonist treated patients. Building on Ovation's existing IBD Omics product, the partnership will help identify optimal drug targets and biomarkers, potentially reducing development costs and improving treatment success rates. The initiative will leverage de-identified, consented samples linked to longitudinal clinical data, including medical records, laboratory results, and claims.
Illumina has launched the MiSeq i100 and MiSeq i100 Plus Systems, featuring breakthrough room-temperature storage technology for sequencing reagents. Led by Associate Director Erin Imsand, the team developed a lyophilization process that transforms reagents into microspheres, eliminating the need for cold storage and dry ice shipping. The technology incorporates over 140 invention disclosures and 60 patent families.
The innovative process removes water content from materials through sublimation, creating stable, dry microspheres that can be stored at room temperature and rehydrated when needed. This advancement eliminates the need for refrigeration and freezer space, potentially revolutionizing how sequencing reagents are stored and handled in laboratories.
Illumina has demonstrated the effectiveness of Whole-Genome Sequencing (WGS) in blood cancer diagnostics through a comprehensive study. The research evaluated WGS performance in identifying variants specific to Acute Myeloid Leukemia (AML), achieving 100% sensitivity including hard-to-find mutations. The study, conducted at Illumina Laboratory Services, achieved a five-day turnaround time and demonstrated a 95% detection rate at 5% variant allele frequency with 140× coverage.
The company's WGS method utilizes their DRAGEN software and will expand Connected Insights functionality in early 2025 to include automated risk stratification for AML samples. This advancement offers a significant improvement over conventional diagnostic methods, which often require multiple tests and have detection capabilities.
Illumina's DRAGEN Secondary Analysis software has received third-party validation from Baylor College of Medicine, with results published in Nature Biotechnology. The study confirms DRAGEN's superior performance in genome analysis, featuring proprietary algorithms developed in-house. The software includes over a dozen specialized variant callers for challenging genome sections and incorporates a pangenome reference to address Eurocentric bias in genetic data.
The validation demonstrated DRAGEN's exceptional accuracy, with competing tools showing up to 470% more errors. Notably, DRAGEN can process whole human genome analysis in just 30 minutes, compared to several days with other tools. The software's comprehensive approach integrates multiple components efficiently, making it particularly valuable for both individual samples and large-scale population studies.
Illumina (NASDAQ: ILMN) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company's executives will deliver a presentation on January 14, 2024, at 9:00 AM Pacific Time (12:00 PM Eastern Time), followed by a Q&A session at approximately 9:20 AM Pacific Time (12:20 PM Eastern Time).
Investors and interested parties can access the webcast through the Investor Info section on investor.illumina.com. A replay of the presentation will be available on the company's website for a minimum of 30 days after the event.
Synaffix has entered into a licensing agreement with Illumina (NASDAQ: ILMN) for its metal-free click chemistry technology. The agreement grants Illumina access to Synaffix's patented technology for use in next-generation sequencing (NGS) products.
Synaffix's technology utilizes a bicyclononyne (BCN) probe for metal-free click chemistry, primarily known for creating antibody-drug conjugates in cancer treatment. This licensing deal represents an expansion of the technology's applications into the diagnostics and sequencing field, aiming to make whole-genome sequencing more accessible.
A comprehensive study by Illumina, Providence, and Microsoft Research demonstrates that a 523-gene comprehensive genomic profiling (CGP) panel significantly improves cancer treatment outcomes. The study, published in the Journal of Clinical Oncology - Oncology Practice, analyzed 3,216 patients with advanced cancers. Key findings show that 67% of tumors contained actionable mutations using CGP, compared to 33% with a 50-gene panel. Patients receiving precision therapy based on CGP results showed median survival of 25 months versus 17 months for those on chemotherapy alone. The panel identified actionable variations in 52% of patients, qualifying them for targeted or immune therapy.